Xynomic Pharmaceuticals (XYNO) the U.S. and China-based oncology drug development company reports that independent Ethics Committees (ECs) at three leading Chinese cancer hospitals have approved of their application to conduct pivotal Phase 3 trial using their investigational product called abexinostat, in combination with pazopanib in patients with renal cell carcinoma. The three clinical research site ECs include Fujian Provincial Hospital, Tongji Medical College in Huazhong University of Science and Technology and Qilu Hospital of Shandong University.
Renal Cell Carcinoma
Also known as kidney cancer in the U.S.; it is estimated that there will be 73,820 new cases with 14,770 deaths.
What is Abexinostat?
Formerly called PCI-24781 it is an experimental drug candidate for drug treatment. IT was developed by Pharmacyclics (acquired by AbbVie)and licensed to Xynomic. The investigational product is currently in Phase II clinical trials for B-cell lymphoma. Pre-clinical study results suggest the potential for the treatment of different types of cancer as well.
Chinese Research Centers/ECs
- Fujian Provincial Hospital
- Tongi Medical College in Huazhong University of Science and Technology
- Qilu Hospital of Shandong University
Founded in 2016, this U.S. and Chinese-based venture have raised approximately $5 million. The emerging venture focuses on in-licensing, developing and commercializing oncology drug candidates in China, US, and rest of the world. The founding executives worked at leading multinational biopharmaceutical companies (Schering, Eli Lilly, Merck, and Roche) in R&D roles. The founders also had successful entrepreneurial experiences including founding, building, and exiting successful US-China biopharmaceutical companies. Xynomic Pharma aims to build a comprehensive clinical and pre-clinical stage oncology pipeline targeting cancers with high prevalence in China, US and the rest of the world. Xynomic Pharma leverages global resources, enabling the company to develop drugs in a cost and time-efficient manner.